ScreenerHero

XTLB XTL Biopharmaceuticals Ltd.

NAS · US · Healthcare · Biotechnology · xtlbio.com
1.980USD-1.98%Mkt Cap: 4.87M $P/E: —

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.87M USD
Enterprise Value4.89M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-6.97M USD
Revenue/Share—
Last Price1.980 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG2.27
EV/EBITDA-3.86
EV/Revenue—
P/S—
P/B—
EPS (TTM)-0.36
EPS (Forward)—
52W Range
1.9750% of range10.28
52W High10.28 USD
52W Low1.975 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE2743.70%
ROA-4198.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.02M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-43.49%
Net Debt-76.00K USD
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity-1.06
Current Ratio0.40
Quick Ratio0.18
Book Value/Sh0.00 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 10, 2017
Splits
Last Split1:4
Split DateMar 25, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.46M
Float1.75M
Insiders21.44%
Institutions0.21%
Short Interest
Short Ratio0.7d
Short % Float0.39%
Short % Out.0.29%
Shares Short7.17K
Short (prev mo.)11.00K
Technical
SMA 502.588 (-23.5%)
SMA 2002.807 (-29.5%)
Beta0.42
S&P 52W Chg15.78%
Avg Vol (30d)11.57K
Avg Vol (10d)7.28K
Technical Indicators
RSI (14)34.8
MACD-0.1549
MACD Signal-0.1342
MACD Hist.-0.0207
BB Upper2.665 USD
BB Middle2.313 USD
BB Lower1.961 USD
BB Width30.43%
ATR (14)0.1873 USD
Vol Ratio (20d)3.40x